about
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function.Liver abnormalities in bowel diseases.Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts.Intestinal microbiota in primary sclerosing cholangitis.Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota.Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation.The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis.The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation.Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease.Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction.Response to 'Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis' by Rühlemann et al.Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiencyAutotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent CohortsGut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida speciesSelective IgA deficiency in humans is associated with reduced gut microbial diversityCirculating markers of gut barrier function associated with disease severity in primary sclerosing cholangitisThe gut microbial influence on cholestatic liver diseaseConsistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis
P50
Q33731986-F66F1C96-0F01-41E1-AB11-CCAECCE33393Q34375055-29626F06-8B40-4C49-8F21-5B79218F4723Q38650368-44F2C76C-7578-42B0-8750-AB1FFA9CF871Q39058967-E5A5F99D-CFA9-4AC0-B63D-4E2417EA51E4Q39305621-9DC63F9C-5485-4D72-992A-806E8E58D09FQ40753393-AA229488-913F-410E-89FF-91AA3DE71CC2Q40787355-DC78C777-CFA9-48EE-B0D9-88C8383B1857Q40794866-81CF6804-BE13-4AB6-A655-B768C354BB21Q49799963-7AD743BC-1403-47A2-8D7E-4B3362C094A6Q50120621-71EB6B62-3B06-4B96-8A93-F034D6680AAFQ54224356-10FE6278-2FFA-4F3B-878D-0D2803013D0AQ54642602-3F4A7D3C-1A75-4345-9B4D-DCF757F24CABQ60907689-7B5EBB7C-F4D5-4249-8B62-375AE08B91B7Q64988395-DD875418-13EE-4372-942F-BDAAE6AD001CQ88006142-C27DD285-C76F-4510-9662-CA93D8481243Q90949889-CCF5CD89-2D9D-4E7D-84DF-7DA923E98925Q91305614-80839B80-652A-483D-AD7D-E82F84DE457EQ91890521-67E3CFA9-63B4-4367-B771-3E2A2FECF392Q92270923-8079E2BA-8446-4C6A-9269-6DDE4B90B38CQ93095433-19E5D04E-5023-4FB8-9CB0-4C1ABFD77EE6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin Kummen
@ast
Martin Kummen
@en
Martin Kummen
@es
Martin Kummen
@nl
Martin Kummen
@sl
type
label
Martin Kummen
@ast
Martin Kummen
@en
Martin Kummen
@es
Martin Kummen
@nl
Martin Kummen
@sl
prefLabel
Martin Kummen
@ast
Martin Kummen
@en
Martin Kummen
@es
Martin Kummen
@nl
Martin Kummen
@sl
P106
P21
P31
P496
0000-0001-9660-6290
P569
2000-01-01T00:00:00Z